End points and clinical trial designs in pulmonary arterial hypertension
Clinical and regulatory perspectives
Marius M. Hoeper, MD*,*,
Ronald J. Oudiz, MD ,
Andrew Peacock, MD ,
Victor F. Tapson, MD ,
Sheila G. Haworth, MD||,
Adaani E. Frost, MD¶ and
Adam Torbicki, MD
* Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany
Division of Cardiology, Harbor—UCLA Medical Center, Torrance, California, USA
Scottish Pulmonary Vascular Unit, Glasgow, Scotland, UK
Pulmonary Hypertension Center, Duke University Medical Center, Durham, North Carolina, USA
|| Institute of Child Health, London, United Kingdom
¶ Baylor College of Medicine, Houston, Texas, USA
Institute of Tuberculosis and Lung Diseases, University of Warsaw, Warsaw, Poland
Manuscript received November 26, 2003;
accepted February 3, 2004.
*
Reprint requests and correspondence: Dr. Marius M. Hoeper, Department of Respiratory Medicine, Hannover Medical School, 30623 Hannover, Germany.
hoeper.marius{at}mh-hannover.de
To date, randomized controlled clinical trials performed in pulmonary arterial hypertension (PAH) have been relatively short-term studies involving mainly patients with advanced disease. The primary end points in these trials have addressed exercise capacity, usually by using the 6-min walk test. Although this approach is still warranted in future trials assessing new treatments, it is likely that the focus will shift toward trials of longer duration, involving patients with less advanced disease, and that different drugs and drug-combination regimens will be compared. In such trials, it is possible that a composite of markers indicating clinical deterioration (e.g., hospitalization for right heart failure, the requirement for the introduction of an alternative treatment, and predefined indicators of worsening exercise tolerance) may be more useful as primary end points. Quality of life will become a very important issue; however, appropriate quality-of-life questionnaires for PAH have yet to be developed. In addition, hemodynamics will likely remain valuable as secondary end points, but future clinical trials should include hemodynamics obtained both during exercise and at rest. Finally, cardiopulmonary exercise testing, echocardiographic studies, and biochemical parameters, such as brain natriuretic peptide or troponin T, may also prove useful as secondary end points in the future.
|
Abbreviations and Acronyms
| | BNP | = brain natriuretic peptide | | CO | = cardiac output | | CPET | = cardiopulmonary exercise testing | | EMEA | = European Agency for the Evaluation of Medicinal Products | | FDA | = Food and Drug Administration | | LV | = left ventricle/ventricular | | NYHA | = New York Heart Association | | PAH | = pulmonary arterial hypertension | | PAP | = pulmonary artery pressure | | PAPm | = mean pulmonary artery pressure | | PCWP | = pulmonary capillary wedge pressure | | PVR | = pulmonary vascular resistance | | QoL | = quality of life | | RV | = right ventricle/ventricular | | VO
2
| = oxygen consumption | | WHO | = World Health Organization |
|
This article has been cited by other articles:
|
|
|
|
 
Y. SCHOINDRE, C. MEUNE, A. T. DINH-XUAN, J. AVOUAC, A. KAHAN, and Y. ALLANORE
Lack of Specificity of the 6-Minute Walk Test as an Outcome Measure for Patients with Systemic Sclerosis
J Rheumatol,
July 1, 2009;
36(7):
1481 - 1485.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. B. Taichman, M. D. McGoon, M. O. Harhay, C. Archer-Chicko, J. S. Sager, M. Murugappan, M. M. Chakinali, H. I. Palevsky, and R. Gallop
Wide Variation in Clinicians' Assessment of New York Heart Association/World Health Organization Functional Class in Patients With Pulmonary Arterial Hypertension
Mayo Clin. Proc.,
July 1, 2009;
84(7):
586 - 592.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. V. McLaughlin, D. B. Badesch, M. Delcroix, T. R. Fleming, S. P. Gaine, N. Galie, J. S. R. Gibbs, N. H. Kim, R. J. Oudiz, A. Peacock, et al.
End Points and Clinical Trial Design in Pulmonary Arterial Hypertension
J. Am. Coll. Cardiol.,
June 30, 2009;
54(1_Suppl_S):
S97 - S107.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Quarck, T. Nawrot, B. Meyns, and M. Delcroix
C-reactive protein a new predictor of adverse outcome in pulmonary arterial hypertension.
J. Am. Coll. Cardiol.,
April 7, 2009;
53(14):
1211 - 1218.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Chemla, V. Castelain, S. Provencher, M. Humbert, G. Simonneau, and P. Herve
Evaluation of Various Empirical Formulas for Estimating Mean Pulmonary Artery Pressure by Using Systolic Pulmonary Artery Pressure in Adults
Chest,
March 1, 2009;
135(3):
760 - 768.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. R. Henkens, C. T.-J. Gan, S. A. van Wolferen, M. Hew, A. Boonstra, J. W. R. Twisk, O. Kamp, E. E. van der Wall, M. J. Schalij, A. Vonk Noordegraaf, et al.
ECG Monitoring of Treatment Response in Pulmonary Arterial Hypertension Patients
Chest,
December 1, 2008;
134(6):
1250 - 1257.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. A. Ghofrani, M. W. Wilkins, and S. Rich
Uncertainties in the Diagnosis and Treatment of Pulmonary Arterial Hypertension
Circulation,
September 9, 2008;
118(11):
1195 - 1201.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. F. Opitz, R. Ewert, W. Kirch, and D. Pittrow
Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter?
Eur. Heart J.,
August 2, 2008;
29(16):
1936 - 1948.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Warwick, P. S. Thomas, and D. H. Yates
Biomarkers in pulmonary hypertension
Eur. Respir. J.,
August 1, 2008;
32(2):
503 - 512.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Provencher, P. Herve, O. Sitbon, M. Humbert, G. Simonneau, and D. Chemla
Changes in exercise haemodynamics during treatment in pulmonary arterial hypertension
Eur. Respir. J.,
August 1, 2008;
32(2):
393 - 398.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Suntharalingam, C. M. Treacy, N. J. Doughty, K. Goldsmith, E. Soon, M. R. Toshner, K. K. Sheares, R. Hughes, N. W. Morrell, and J. Pepke-Zaba
Long-term Use of Sildenafil in Inoperable Chronic Thromboembolic Pulmonary Hypertension
Chest,
August 1, 2008;
134(2):
229 - 236.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. E. Ventetuolo, R. L. Benza, A. J. Peacock, R. T. Zamanian, D. B. Badesch, and S. M. Kawut
Surrogate and Combined End Points in Pulmonary Arterial Hypertension
Proceedings of the ATS,
July 15, 2008;
5(5):
617 - 622.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Chen, D. B. Taichman, and R. L. Doyle
Health-related Quality of Life and Patient-reported Outcomes in Pulmonary Arterial Hypertension
Proceedings of the ATS,
July 15, 2008;
5(5):
623 - 630.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A E Lammers, A A Hislop, Y Flynn, and S G Haworth
The 6-minute walk test: normal values for children of 4-11 years of age
Arch. Dis. Child.,
June 1, 2008;
93(6):
464 - 468.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. G. Stevinson, J. Hernandez-Nino, G. Rose, and J. A. Kline
Echocardiographic and functional cardiopulmonary problems 6 months after first-time pulmonary embolism in previously healthy patients
Eur. Heart J.,
October 2, 2007;
28(20):
2517 - 2524.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. L. Helman Jr, A. W. Brown, J. L. Jackson, and A. F. Shorr
Analyzing the Short-term Effect of Placebo Therapy in Pulmonary Arterial Hypertension: Potential Implications for the Design of Future Clinical Trials
Chest,
September 1, 2007;
132(3):
764 - 772.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G.-P. Diller and M. A. Gatzoulis
Pulmonary Vascular Disease in Adults With Congenital Heart Disease
Circulation,
February 27, 2007;
115(8):
1039 - 1050.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. M. Hoeper, S. H. Lee, R. Voswinckel, M. Palazzini, X. Jais, A. Marinelli, R. J. Barst, H. A. Ghofrani, Z.-C. Jing, C. Opitz, et al.
Complications of Right Heart Catheterization Procedures in Patients With Pulmonary Hypertension in Experienced Centers
J. Am. Coll. Cardiol.,
December 19, 2006;
48(12):
2546 - 2552.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. V. McLaughlin, R. J. Oudiz, A. Frost, V. F. Tapson, S. Murali, R. N. Channick, D. B. Badesch, R. J. Barst, H. H. Hsu, and L. J. Rubin
Randomized Study of Adding Inhaled Iloprost to Existing Bosentan in Pulmonary Arterial Hypertension
Am. J. Respir. Crit. Care Med.,
December 1, 2006;
174(11):
1257 - 1263.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Distler, F. Behrens, D. Huscher, I. Foeldvari, A. Zink, P. Nash, C. P. Denton, M. Humbert, M. Matucci-Cerinic, J. Seibold, et al.
Need for improved outcome measures in pulmonary arterial hypertension related to systemic sclerosis
Rheumatology,
December 1, 2006;
45(12):
1455 - 1457.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Cenedese, R. Speich, L. Dorschner, S. Ulrich, M. Maggiorini, R. Jenni, and M. Fischler
Measurement of quality of life in pulmonary hypertension and its significance
Eur. Respir. J.,
October 1, 2006;
28(4):
808 - 815.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Peacock, G. Simonneau, and L. Rubin
Controversies, Uncertainties and Future Research on the Treatment of Chronic Thromboembolic Pulmonary Hypertension
Proceedings of the ATS,
September 1, 2006;
3(7):
608 - 614.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Bonderman, R. Nowotny, N. Skoro-Sajer, J. Jakowitsch, C. Adlbrecht, W. Klepetko, and I. M. Lang
Bosentan Therapy for Inoperable Chronic Thromboembolic Pulmonary Hypertension
Chest,
October 1, 2005;
128(4):
2599 - 2603.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. J. Rubin and D. B. Badesch
Evaluation and Management of the Patient with Pulmonary Arterial Hypertension
Ann Intern Med,
August 16, 2005;
143(4):
282 - 292.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
